Neurocrine (NBIX) Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA capsules on the physical, social and ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. (PRNewsfoto ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. The live webcasts can be accessed on Neurocrine ...

I review privacy tools like hardware security keys, password managers, private messaging apps and ad-blocking software. I also report on online scams and offer advice to families and individuals ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...

For the year to December 2024, Neurocrine Biosciences had an accrual ratio of -0.15. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ratings ...

Neurocrine (NBIX) Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares ...